Cerevance to Join Precision Neurotherapeutics Panel at 2024 BIO International Convention

Cerevance, a company dedicated to the development of precise therapeutics for central nervous system (CNS) disorders, has announced that its CEO, Craig Thompson, will be part of a panel at the 2024 BIO International Convention in San Diego, CA. This convention will be held from June 3 to June 6, 2024.

Craig Thompson will join the panel titled "Targeting the Brain: How Biotech is Uncovering the Biology of Brain Disease for Precision Neurotherapeutics." The session is scheduled for Tuesday, June 4, from 11 AM PT to 12 PM PT at the San Diego Convention Center, Ballroom 26A.

Cerevance focuses on creating precision treatments for CNS disorders, which include chronic neurodegenerative diseases like Alzheimer's, Parkinson's, frontotemporal dementia, and amyotrophic lateral sclerosis. By leveraging a substantial database of over 15,000 human brain tissue samples, Cerevance has been able to gather extensive expression and epigenetic data. This data is crucial in identifying the most promising targets for the next generation of CNS disorder treatments.

The company employs its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform and advanced machine learning techniques to explore gene expression in specific cell types. This helps in recognizing novel targets that are uniquely expressed in circuits affected by diseases or are altered in disease conditions. The combination of this research data and the expertise of Cerevance’s team of scientists and drug developers is driving the clinical advancement of multiple therapeutics in their pipeline.

Among the leading candidates in their pipeline are CVN424, CVN766, and CVN293. CVN424 is a pioneering non-dopamine therapy that has shown potential in alleviating both motor and non-motor symptoms of Parkinson's disease and may also have the ability to delay the progression of the disease. CVN766 is a highly selective antagonist of the orexin 1 receptor, which could benefit those suffering from psychiatric conditions such as schizophrenia, anxiety/panic, binge eating/obesity, substance use disorder, and Prader-Willi Syndrome. Lastly, CVN293 is a novel inhibitor of potassium efflux in glia, helping regulate the inflammasome in people living with neurodegenerative diseases.

Cerevance's comprehensive pipeline is focused on bringing substantial improvements to the lives of patients affected by CNS disorders through innovative and precise therapeutic solutions.